We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Webinar Recordings » FDA and EU Inspections – Webinar Recording/Transcript

Other Options

USB Audio Recording/Transcript - Sept. 27, 2019

$287.00

USB Audio Recording/Transcript - Sept. 27, 2019

$258.00

USB Audio Recording/Transcript - Sept. 27, 2019

$244.00

USB Audio Recording/Transcript - Sept. 27, 2019

$230.00

USB Audio Recording/Transcript - Sept. 27, 2019

$215.00
webinar recording

FDA and EU Inspections – Webinar Recording/Transcript

$287.00
Webinar Recordings

Product Details

FDA and EU Inspections — The Mutual Recognition Agreement: What’s Next?

It’s been seven years since FDASIA was enacted and the path to globalized GMP inspections of drugmakers is complete at last. The Mutual Recognition Agreement (MRA) provides for inspection cooperation among the FDA and the 28 member nations of the EU. So ...

What happens now???

Are good things on your horizon ... or glitches ... or both? Two leading Washington consultants, Cynthia Schnedekar Esq. and Elizabeth (“Liz”) Oestreich Esq. of Greenleaf Health Inc. are your guides on a 90-minute exploration of the new inspections landscape.

Presentation Takeaways:

  • MRA Timeline: The Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 and what it has led to
  • Benefits so far: How inspectors are using each other's inspections to maintain a risk-based approach ... potential benefits for U.S. drug safety
  • And costs: How the MRA may complicate regulatory and compliance operations ... which inspections FDA will continue to perform ... which will go to EU member states
  • What’s next for: FDA capability assessments ... possibility of duplicating the MRA model in other regions ... potential impact of ‘Brexit’ on the MRA

Drugmaking today is a global business. Even if EU sales represent a small portion of your sales now, that can change down the road. Protect yourself!

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing